MPA and MIA collaboration
7 November 2019
In a boost for melanoma patients across the country, Melanoma Patients Australia and Melanoma Institute Australia have announced a new multi-year agreement to provide enhanced support services for patients nationally. The agreement was announced at a Melanoma Information Forum held in Sydney, jointly hosted by both organisations. The forum detailed updates on treatments, surgery and strategies for living well and included expert advice from MIA Co-Medical Directors Professor Georgina Long and Professor Richard Scolyer.
The new MPA/MIA agreement will focus on:
- Introduction of a Tele Health Nurse Pilot Program to provide better access of services for melanoma patients
- Increased capacity and expertise of MPA’s Peer to Peer volunteer facilitators and volunteer support staff
- Enhanced face to face support groups within NSW and integration of these into MPA’s national support network
- Joint involvement in events including patient information sessions and MIA’s national Melanoma March campaign.
‘Both organisations look forward to partnering more closely to deliver enhanced support services to melanoma patients nationally,’ said Matthew Browne, CEO of Melanoma Institute Australia.
‘We are very excited and proud to be working with the incredible team at Melanoma Institute Australia,’ said Victoria Beedle, CEO of Melanoma Patients Australia. ‘MIA’s goal is zero deaths from melanoma achieved through research into new and exciting treatments for patients. With survival rates continuing to improve, the need for this collaboration to strengthen the Support Services available to our patients and families, is, thankfully, even greater. With this partnership we will achieve national synergies and strength from our collective efforts to raise awareness of melanoma in the community.’
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.